The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Multi Stakeholder Workshop April 2022

Measurable Residual Disease (MRD) and Circulating Tumour Nucleotides (ct DNA) in cancer drug development

 

25-26 April 2022, Hybrid Workshop – Amsterdam, NL

PROGRAMME COMMITTEE
  • Committee chair: Axel Glasmacher (CDDF, DE)
  • John Smyth (CDDF, UK)
  • Veerendra Munugalavadla (AstraZeneca)
  • Reshma Patel (Johnson & Johnson)
  • Natalie Dimier (Roche)
  • Hans Scheurer (MPE, NL)
COMMITTEE ADVISOR
  • Ralf Herold (EMA, NL)
TARGET AUDIENCE

The target is a multidisciplinary audience of academic representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical industry, HTAs, and patient advocates.

 

DRAFT PROGRAMME 

To view the draft programme, click HERE

 

MEETING VENUE & VIRTUAL PLATFORM

NHOW Amsterdam RAI

Europaboulevard 2b, 1078 RV Amsterdam, Pays-BasNL

Virtual platform: to be announced

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

info@cddf.org
Tel: +32 2 880 62 70